# CooperCompanies (COO) Q3 2025 Financial Results Summary
San Ramon, Calif., August 27, 2025 — CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2025.
## Key Financial Highlights:
– **Revenue**:
– Increased by **6%** year-over-year to **$1,060.3 million**.
– CooperVision (CVI) revenue increased by **6%** to **$718.4 million**.
– CooperSurgical (CSI) revenue increased by **4%** to **$341.9 million**.
– **Earnings Per Share (EPS)**:
– GAAP diluted EPS: **$0.49**, down **6%** from **$0.52** in the same quarter last year.
– Non-GAAP diluted EPS: **$1.10**, up **15%** from **$0.96** in the same quarter last year.
## Operating Results:
– **Revenue Analysis**:
– Total revenue of **$1,060.3 million** represented a **6%** increase from last year’s third quarter.
– Revenue growth on a constant currency basis: **3%**.
– Organic revenue growth stood at **2%**.
– **Margins**:
– Gross margin: **65%**, down from **66%** year-over-year.
– Non-GAAP gross margin: **67%**, an increase of **70 basis points** year-over-year.
– Operating margin: **17%**, decreased from **19%** year-over-year.
– Non-GAAP operating margin: **26%**, an increase of **60 basis points** year-over-year.
– **Interest Expense**:
– Interest expense: **$25.4 million**, down from **$28.5 million** in Q3 2024.
– Non-GAAP interest expense was **$24.7 million**, down from **$27.1 million**.
– **Cash Flow**:
– Cash provided by operations: **$261.5 million**.
– Capital expenditures: **$96.9 million**.
– Free cash flow: **$164.6 million**.
## Segment Performance:
### CooperVision (CVI):
– Total CVI revenue: **$718.4 million**, a **6%** increase year-over-year.
– Revenue by category:
– Toric and multifocal: **$358.8 million**, **10%** growth.
– Sphere and other: **$359.6 million**, **3%** growth.
– **Geographic Revenue**:
– Americas: **$286.0 million**, **2%** increase.
– EMEA: **$292.1 million**, **14%** increase.
– Asia Pacific: **$140.3 million**, **1%** increase.
### CooperSurgical (CSI):
– Total CSI revenue: **$341.9 million**, a **4%** increase year-over-year.
– Revenue by category:
– Office and surgical: **$204.8 million**, **3%** growth.
– Fertility: **$137.1 million**, **6%** growth.
## Share Repurchase Activity:
– During Q3 2025, CooperCompanies repurchased **$52.1 million** of common stock, corresponding to approximately **724.3 thousand shares** at an average price of **$71.97** per share.
– Remaining share repurchase program availability: **$163.6 million**.
## Financial Guidance:
– Update for Q4 2025:
– Revenue expected between **$1,049 – $1,069 million** (organic growth **2% to 4%**).
– CVI revenue expected between **$700 – $713 million** (organic growth **2% to 4%**).
– CSI revenue expected between **$350 – $356 million** (organic growth **2% to 4%**).
– Fiscal 2025 non-GAAP diluted EPS guidance of **$4.08 – $4.12**.
## Summary:
CooperCompanies reported a solid performance in Q3 2025, showcasing revenue growth across its segments and a notable increase in non-GAAP earnings. The company maintained strong cash flow while executing a share repurchase program, indicating a commitment to returning value to shareholders. The outlook for the fourth quarter and beyond remains positive, with expectations for continued revenue growth driven by its CooperVision and CooperSurgical brands.
Here are the extracted tables from the press release:
| Three Months Ended July 31, | Nine Months Ended July 31, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Net sales | $1,060.3 | $1,002.8 | $3,027.3 | $2,877.0 |
| Cost of sales | 368.3 | 339.8 | 996.0 | 959.0 |
| Gross profit | 692.0 | 663.0 | 2,031.3 | 1,918.0 |
| Selling, general and administrative expense | 421.7 | 381.1 | 1,208.6 | 1,142.3 |
| Research and development expense | 44.6 | 39.0 | 130.8 | 117.4 |
| Amortization of intangibles | 50.0 | 50.4 | 149.4 | 151.0 |
| Operating income | 175.7 | 192.5 | 542.5 | 507.3 |
| Interest expense | 25.4 | 28.5 | 75.6 | 87.3 |
| Other expense, net | -1.6 | 0.3 | 17.2 | 6.3 |
| Income before income taxes | 151.9 | 163.7 | 449.7 | 413.7 |
| Provision for income taxes | 53.6 | 59.0 | 159.4 | 138.9 |
| Net income | $98.3 | $104.7 | $290.3 | $274.8 |
| Earnings per share – diluted | $0.49 | $0.52 | $1.45 | $1.37 |
| Number of shares used to compute diluted earnings per share | 200.0 | 200.6 | 200.6 | 200.3 |
—
| ASSETS | July 31, 2025 | October 31, 2024 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $124.9 | $107.6 |
| Trade receivables, net | 792.3 | 717.0 |
| Inventories | 881.0 | 802.7 |
| Prepaid expense and other current assets | 339.6 | 324.2 |
| Total current assets | 2,137.8 | 1,951.5 |
| Property, plant and equipment, net | 1,988.7 | 1,863.4 |
| Goodwill | 3,861.8 | 3,838.4 |
| Other intangibles, net | 1,635.9 | 1,791.0 |
| Deferred tax assets | 2,099.2 | 2,210.3 |
| Other assets | 653.3 | 660.6 |
| Total assets | $12,376.7 | $12,315.2 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Short-term debt | $46.9 | $33.3 |
| Accounts Payable | 255.9 | 260.5 |
| Employee compensation and benefits | 181.1 | 174.8 |
| Deferred revenue | 126.6 | 129.9 |
| Other current liabilities | 399.6 | 424.3 |
| Total current liabilities | 1,010.1 | 1,022.8 |
| Long-term debt | 2,431.4 | 2,550.4 |
| Deferred tax liabilities | 101.8 | 96.0 |
| Long-term tax payable | 17.8 | 57.5 |
| Deferred revenue | 199.4 | 193.3 |
| Other liabilities | 263.2 | 311.6 |
| Total liabilities | 4,023.7 | 4,231.6 |
| Stockholders’ equity | 8,353.0 | 8,083.6 |
| Total liabilities and stockholders’ equity | $12,376.7 | $12,315.2 |
